GS-5816

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
01220142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Preclinical characterization of velpatasvir (VEL; GS-5816), an inhibitor of the hepatitis C virus (HCV) NS5A protein… (More)
  • table 2
  • table 1
  • table 3
  • table 4
  • table 5
Is this relevant?
Review
2017
Review
2017
OBJECTIVES To review the pharmacology, efficacy, and safety of sofosbuvir/velpatasvir in the treatment of patients with hepatitis… (More)
  • table 1
  • table 2
Is this relevant?
2016
2016
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with… (More)
Is this relevant?
2016
2016
BACKGROUND AND OBJECTIVES Velpatasvir (VEL; GS-5816) is a potent, pangenotypic hepatitis C virus (HCV), non-structural protein 5A… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2015
2015
GS-5816 is an inhibitor of the hepatitis C virus (HCV) NS5A protein that has demonstrated pan-genotypic activity and a high… (More)
Is this relevant?
Review
2014
Review
2014
Some direct-acting antiviral agents for hepatitis C virus (HCV), such as telaprevir and boceprevir have been available since 2011… (More)
Is this relevant?